NRIX Latest Press Releases

-- October 12, 2026 --

Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update Globe Newswire 4:05 PM

-- October 7, 2026 --

Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia Globe Newswire 1:00 AM

-- October 5, 2026 --

Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences Globe Newswire 7:00 AM

-- September 29, 2026 --

Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer Globe Newswire 7:00 AM

-- September 1, 2026 --

Nurix Therapeutics to Participate in Upcoming September Investor Conferences Globe Newswire 8:00 AM

-- August 20, 2026 --

Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer Globe Newswire 7:00 AM

-- August 4, 2026 --

Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader Globe Newswire 7:00 AM

Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Globe Newswire 1:00 AM

-- July 21, 2026 --

Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology Globe Newswire 4:01 PM

-- July 9, 2026 --

Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Globe Newswire 4:01 PM

-- July 6, 2026 --

A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs PRNewswire 11:20 AM

-- June 11, 2026 --

Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy Globe Newswire 7:00 AM

-- June 8, 2026 --

Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology Globe Newswire 1:00 AM

Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology Globe Newswire 1:00 AM

Market Data Delayed 15 Minutes